Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina

Abstract

Background A first-dose of various vaccines provides acceptable protection against infections by SARS-CoV-2 and evolution to the most severe forms of COVID-19. The recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), was proven efficacious but information about effectiveness in the real-world setting is lacking. The aim of our study was to investigate the association between the rollout of the first component (rAd26) of Gam-COVID-Vac and PCR-positive tests, hospitalisations and deaths. Methods We conducted a retrospective cohort study which analyzed individuals aged 60-79 who self-registered in the online vaccination system of the Province of Buenos Aires, Argentina, from December 29, 2020 to March 21, 2021. Exclusion criteria were having a previous positive RT-PCR or antigen tests for SARS-CoV-2, having received other vaccines, or two doses of any vaccine. Proportions of new laboratory-confirmed SARS-CoV-2 infections, hospitalisations and deaths until 83 days of vaccination were compared between vaccinated and unvaccinated subjects. Vaccine effectiveness for the three outcomes was calculated as (1–OR) × 100. Kaplan-Meier cumulative incidence curves were constructed. Findings During the study period 415995 registered subjects received the first component of Gam-COVID-Vac; 40387 belonged to the 60-79 age group, and were compared to 38978 unvaccinated. Vaccine effectiveness for preventing laboratory-confirmed infections was 78•6% [CI 95% 74·8 - 81·7]; and for reducing hospitalizations and deaths was, respectively, 87·6% [CI 95% 80·3 - 92·2] and 84·8% [CI 95% 75·0 - 90·7]. Effectiveness was high across all subgroups. Interpretation Similarly to other vaccines, the administration of one dose of Gam-COVID-Vac was effective for a wide range of COVID-19–related outcomes. Funding This study did not receive any funding.

Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study

“…These findings are consistent with reports from different contexts and populations for ChAdOx1 nCoV-19 and for other vaccines. 8 , 25 , 26 , 27 , 28 Our results suggest that, given the difficulty in accessing vaccines, a one-dose prioritisation schedule seems to be an appropriate strategy for prevention of death, not only for previously evaluated vaccines but also for rAd26-rAd5.…”

Long-term analysis of antibodies elicited by SPUTNIK V: A prospective cohort study in Tucumán, Argentina

“… 21 The few available studies, pre-prints and official reports from ministries of health of different nations have confirmed in large cohorts the safety and efficacy of SPUTNIK V originally reported in Phase I/II and III studies. 21 , 37 , 38 Nevertheless, SPUTNIK V has yet to be approved for emergency use by the World Health Organization and the European Medicines Agency, the former of which is critical for this vaccine to be deployed to low-income nations through the COVID-19 Global Access (COVAX) initiative. 21 This shortage of peer-reviewed published data is in stark contrast to the plethora of studies and wealth of information regarding the BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna/NIAID) and AZD1222 (AstraZeneca/University of Oxford) vaccines.…”

One-shot immunization with Sputnik Light (the first component of Sputnik V vaccine) is effective against SARS-CoV-2 Delta variant: efficacy data on the use of the vaccine in civil circulation in Moscow

“…There are few data on the effectiveness of the single-dose vaccine. Effectiveness of the Sputnik V first component in 60-79-years-old group in study in Argentina was 78.6% in the December 29, 2020 to March 21, 2021 period [24].…”